by The human microbiome refers to the microorganisms that live within the human body and on its surfaces, including bacteria, archaea, protists, and fungi. These microorganisms influence various functions in the human body including metabolism, digestion, and immune response. Advances in DNA sequencing technologies have enabled a better understanding of the role of human microbiome in health and disease.
The global Human Microbiome Market is estimated to be valued at US$ 4248.55 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: Growing adoption of next-generation sequencing (NGS) technologies has accelerated research in the human microbiome. NGS allows fast, cost-effective and high-throughput sequencing of bacterial communities. It has enabled large-scale sequencing of microbiomes from various body sites and disease states. NGS technologies such as Illumina sequencing are being widely used by researchers to study the interactions between the human microbiome and various diseases including obesity, diabetes, and cancer. This has enhanced our understanding of how alterations in the gut microbiome composition may influence disease pathogenesis, progression or treatment response.
SWOT Analysis
Strength: The human microbiome market provides opportunities for developing therapeutics targeting gut health issues. Growing awareness about gut health and its link to various diseases is driving the market growth.
Weakness: Limited understanding of role of gut microbiota in various diseases. High costs associated with development and commercialization of microbiome-based therapies.
Opportunity: Rapid advancements in sequencing technologies and bioinformatics are enabling better characterization of human microbiome. This is expected to translate into development of novel microbiome-based diagnostics and therapeutics.
Threats: Stringent regulatory requirements for approval of microbiome-based therapies. Ethical issues related to manipulation of human microbiome.
Key Takeaways
The Global Human Microbiome Market Size is expected to witness high growth over the forecast period owing to growing incidence of chronic diseases associated with gut dysbiosis and increasing investments in microbiome research. The global Human Microbiome Market is estimated to be valued at US$ 4248.55 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
Regional analysis- North America is currently the dominant region for the human microbiome market due to presence of major players and availability of funding for research activities in the region. The Asia Pacific is expected to witness fastest growth over the coming years supported rising healthcare expenditure and increasing geriatric population in the region.
Key players- Key players operating in the human microbiome market are Diageo plc, Pernod-Ricard SA, Constellation Brands Inc., Brown-Forman Corporation, Remy Cointreau SA. These players are focused on collaborations and partnerships with research institutes to develop novel microbiome-based therapies and diagnostics.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
